COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Seizures Post Intracerebral Hemorrhage

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01115959
Recruitment Status : Completed
First Posted : May 4, 2010
Last Update Posted : June 12, 2014
Information provided by (Responsible Party):
Dr. Yair Lampl, Wolfson Medical Center

Brief Summary:
This study examines early antiepileptic treatment with valproic acid for acute cerebral hemorrhage against a placebo group immediately post event to evaluate the outcome of these patients regarding seizures and neurological outcome.

Condition or disease Intervention/treatment Phase
Post Cerebral Hemorrhage Drug: valproic acid Drug: placebo bid Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Are Post Intracerebal Hemorrhage Prevented By Anti-Epileptic Treatment?
Study Start Date : February 2003
Actual Primary Completion Date : October 2008
Actual Study Completion Date : December 2008

Arm Intervention/treatment
Active Comparator: valproic acid
Valproic acid given orally 400mg twice daily
Drug: valproic acid
treatment of 1 month dosage of 400 mg BID

Drug: placebo bid
Placebo Comparator: placebo
Placebo twice daily for one month
Drug: placebo bid

Primary Outcome Measures :
  1. number of seizures [ Time Frame: study drug for 1 month and 1 year follow up ]

Secondary Outcome Measures :
  1. neurological outcome NIHSS [ Time Frame: during 1 month study drug and 1 year post follow up ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • cerebral hemorrhage spontaneous

Exclusion Criteria:

  • early seizures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01115959

Sponsors and Collaborators
Wolfson Medical Center
Layout table for investigator information
Principal Investigator: ronit gilad, md E Wolfson med center
Principal Investigator: ronit gilad, md E wofson med center
Layout table for additonal information
Responsible Party: Dr. Yair Lampl, Professor Yair Lampl, Wolfson Medical Center Identifier: NCT01115959    
Other Study ID Numbers: 001
First Posted: May 4, 2010    Key Record Dates
Last Update Posted: June 12, 2014
Last Verified: May 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Cerebral Hemorrhage
Pathologic Processes
Intracranial Hemorrhages
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Valproic Acid
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
GABA Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs